HPTN 084-01

Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV among Adolescent Females – A Sub-study of HPTN 084.


Despite reductions in other age groups, the number of deaths attributable to HIV is rising in the adolescent age group. As with many daily medication regimens, the effectiveness of oral PrEP is highly dependent on adherence to the prescribed drugs. This appears to be particularly true for adolescents and young adults. Adult safety data on long-acting cabotegravir (CAB LA) will need to be expanded to adolescents in order to license the product for adolescents under the age of 18.


  • Prof Sinead Delany-Moretlwe, IOR
  • Dr Carrie-Anne Mathew,Sub Investigator
  • Dr Elizabeth Roos, Dr Nicole Poovan,Sub Investigator

Latest Update:

April 2024

For more about HPTN 084-01 please email

Study Brief

HPTN 084-01

Stay up to date

Get updates on news, resources, events and happenings from Wits RHI.